Canada markets close in 7 minutes

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
36.21+0.64 (+1.79%)
As of 03:53PM EDT. Market open.

Celldex Therapeutics, Inc.

Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908 200 7500
https://www.celldex.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees160

Key Executives

NameTitlePayExercisedYear Born
Mr. Anthony S. Marucci M.B.A.Founder, President, CEO & Director1.27MN/A1962
Dr. Tibor Keler Ph.D.Founder, Chief Scientific Officer & Executive VP810.39kN/A1959
Mr. Sam MartinSenior VP, CFO, Secretary & Treasurer676.87kN/A1971
Dr. Margo Heath-Chiozzi M.D.Senior Vice President of Regulatory Affairs667.21kN/A1957
Dr. Diane C. Young M.D.Senior VP & Chief Medical Officer696.45kN/A1957
Prof. Joseph P. Schlessinger Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1945
Ms. Sarah CavanaughSenior Vice President of Corporate Affairs & AdministrationN/AN/A1975
Mr. Freddy A. Jimenez Esq.Senior VP & General Counsel579.7kN/A1969
Dr. Ronald A. PepinChief Business Officer & Senior VP441.84kN/A1956
Ms. Elizabeth CrowleyChief Product Development Officer & Senior VP507.24kN/A1972
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Corporate Governance

Celldex Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2024 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.